Clinical Trial: Phase II Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: An Open Label, Phase II Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation
Brief Summary: To determine if Rituximab administered after allogeneic transplantation decreases the incidence of chronic GvHD
Detailed Summary: To test if prophylactic Rituximab given to 35 patients 60-90 days after allogeneic transplantation will prevent chronic Graft-versus-Host Disease
Sponsor: Stanford University
Current Primary Outcome: chronic GVHD incidence [ Time Frame: 1.5 years ]
Original Primary Outcome: Chronic GVHD
Current Secondary Outcome:
- Relapse [ Time Frame: 5 years ]
- nonrelapse mortality [ Time Frame: 5 years ]
Original Secondary Outcome: Relapse, non-relapse mortality
Information By: Stanford University
Dates:
Date Received: September 14, 2005
Date Started: June 2005
Date Completion:
Last Updated: March 11, 2011
Last Verified: March 2011